Chime stock slides nearly 4% in year-end trade as fintechs wobble
31 December 2025
1 min read

Chime stock slides nearly 4% in year-end trade as fintechs wobble

NEW YORK, December 31, 2025, 13:38 ET — Regular session

  • Chime Financial shares fell about 3.9% to $25.30 in the final session of 2025.
  • Tech-led weakness kept U.S. stocks slightly lower in holiday-thin trading.
  • Investors are looking ahead to interest-rate signals and Chime’s next quarterly update.

Chime Financial (CHYM.O) shares fell about 3.9% to $25.30 on Wednesday, extending a pullback in the consumer fintech stock on the last trading day of 2025. The shares traded between $25.30 and $26.32 after opening at $26.29.

The late-December tape is often noisy. Trading volumes can thin out around holidays, and that can amplify swings as investors rebalance books into year-end.

That matters for Chime because newer, growth-leaning fintech listings tend to react quickly when investors rotate between riskier names and defensive corners of the market. Rate expectations also loom large: higher yields typically pressure valuations for companies where profits are expected further out.

U.S. stocks edged lower around midday as technology shares weighed on the major indexes, Reuters reported, with markets set to close on Thursday for New Year’s Day. “I do not expect that the last few days will have so much bearing on the performance of the next year,” said Giuseppe Sette, co-founder and president of Reflexivity. 1

Moves across listed fintech were mixed. SoFi Technologies was down about 0.8%, while PayPal slipped about 0.8%.

Chime sells mobile banking and payments products, including checking accounts and debit and credit cards, with banking services provided through partner banks. 2

The company became publicly traded in June after pricing its initial public offering at $27 a share, raising $864 million, a Reuters report showed at the time. 3

Chime’s last quarterly update in November showed faster growth and a raised 2025 revenue forecast, alongside a $200 million share repurchase program. The company said third-quarter revenue rose 29% to $544 million, active members climbed 21% to 9.1 million and purchase volume increased 15% to $32.3 billion; Chief Financial Officer Matt Newcomb also pointed to member spending skewing toward essentials such as groceries and gas. 4

Investors will now look for signs that member growth and card spending stay resilient after the holidays, and that higher engagement translates into improving profitability. Watchpoints include transaction-driven revenue, credit performance where applicable, and how much operating costs rise as the company pushes new products.

Macro signals remain a live wire for fintech shares. The Federal Reserve’s latest meeting minutes highlighted divisions among policymakers over the balance of risks for inflation and the economy, Reuters reported, keeping rate expectations in play heading into 2026. 5

With the New Year’s Day market closure interrupting the flow of trading, attention turns to early-January data that can reset rate bets. The Bureau of Labor Statistics has scheduled the December employment report for Jan. 9 at 8:30 a.m. ET. 6

Stock Market Today

NASA’s SPHEREx spots interstellar comet 3I/ATLAS flaring on its way out — and the chemistry surprised scientists

NASA’s SPHEREx spots interstellar comet 3I/ATLAS flaring on its way out — and the chemistry surprised scientists

7 February 2026
NASA’s SPHEREx telescope detected interstellar comet 3I/ATLAS sharply brightening in December 2025 as it left the solar system, with infrared data revealing a surge of gas and dust, including water vapor and organic molecules. The comet, only the third confirmed interstellar object, passed no closer than 1.8 astronomical units from Earth. China’s Tianwen-1 Mars orbiter also captured images of the comet.
AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Walmart stock slips in thin New Year’s Eve session after CEO sale filing
Previous Story

Walmart stock slips in thin New Year’s Eve session after CEO sale filing

India freezes PPF, SCSS and Sukanya Samriddhi rates for Jan–Mar 2026 — what savers earn now
Next Story

India freezes PPF, SCSS and Sukanya Samriddhi rates for Jan–Mar 2026 — what savers earn now

Go toTop